Incyte Corp.

INCY

$80.68

+16.5% last 12 months

Jim Simons Holding value: $391 Million Cathie Wood Holding value: $83.1 Million Jeremy Grantham Holding value: $30.1 Million Ray Dalio Holding value: $27.8 Million Ken Griffin Holding value: $3.55 Million Ken Fisher Holding value: $2.92 Million Joel Greenblatt Holding value: $1.5 Million Steven Cohen Holding value: $0 Mario Gabelli Holding value: $0 Stanley Druckenmiller Holding value: $0 George Soros Holding value: $0 Bill Gates Holding value: $0

Market Cap

$17.3 Billion

The market capitalization is the market value of the company. It is the sum of the value of all outstanding shares.

52 Week Range

$63.40 - $84.86

The lowest and highest price in the last 52 weeks.

Price-Earnings Ratio

19.75x

The price-earnings ratio is the ratio between the price per share (stock price) and the earnings per share. It indicates the percentage of the price per share (stock price) that is generated in earnings in the last 12 months.

Dividends per Share

$0.00 (0.0%)

Dividends per share is the amount of dividends paid out to the shareholder of a single share in the last 12 months. The percentage indicates the ratio of the company's annual dividend compared to its current price per share (stock price).

Revenue & Earnings

Balance Sheet

Share Statistics

Compare to
Market
Industry
Market Cap The market value of the company. It's calculated by multiplying the share price by the number of outstanding shares. $17.3 Billion
Enterprise Value A measure of a company's total value. This includes market cap, cash, and debt. $14.4 Billion
Dividend Yield Yearly payout to shareholders per share. The percentage indicates the payout in relation to the share price. $0.00 (0.0%)
1 Year Return Profit or loss of share price change plus dividend yield. +16.5%
52-Week High Highest share price in the last 52 weeks. $84.86
52-Week Low Lowest share price in the last 52 weeks. $63.40
Beta Beta indicates the volatility of a stock compared to the market. Higher beta means more volatile and thus potentially higher risk and return. 0.6
Outstanding Shares The number of shares the company has issued and are held by stockholders. 222 Million
Avg 30 Day Volume The number of shares traded in the last 30 days. 1.5 Million

Valuation

Compare to
Market
Industry
P/E Ratio Ratio between share price and earnings per share. A low ratio could indicate that the stock is undervalued or investors aren't expecting high growth. A high ratio could indicate that the stock is overvalued or investors are expecting high growth. 19.75
PEG The ratio between the P/E ratio and the growth rate of the company's earnings per share in the last twelve months. A lower PEG could mean that a stock is undervalued. -52.04
Earnings per Share Earnings divided by outstanding shares. Higher EPS indicates greater value. $3.93
Price to Sales Ratio Market cap divided by the revenue in the most recent year. 5.76
Price to Book Ratio Price to Book Ratio is the Market cap divided by the Book value of the company 4.48
Enterprise Value to Revenue Enterprise value divided by revenue 4.31
Enterprise Value to EBIT Enterprise Value divided by EBIT 22.93
Total Debt to Enterprise Value Total debt divided by enterprise value 0.0
Debt to Equity A higher ratio indicates a higher risk. However, the ratio is difficult to compare between industries where common amounts of debt vary. 0.01

Profitability

Compare to
Market
Industry
Revenue Revenue is the sum of all cash flow into the company. $3.33 Billion
Gross Profit Gross profit is the profit after subtracting the costs of making and selling its products or the costs of providing its services. It indicates the efficiency of using their resources to produce goods or services. $3.14 Billion
EBIT Earnings before tax and interest payments. $626 Million
Net Income Net Income is the profit after all expenses have been deducted from the total revenue. $876 Million
Profit Margin Net income divided by revenue of the last 4 quarters. It indicates the company's profitability. 26.30%
Quarterly Earnings Growth (YoY) The rate at which the company's net income has increased to the same quarter one year ago. -37.9%
Return on Equity Equity divided by market cap. 20.73%
Return on Assets Indicates a company's profitability in relation to its total assets. 15.90%
Return on Invested Capital Return on invested capital (ROIC) is net income after dividends divided by the sum of debt and equity. It shows how effective a company is at turning capital invested by shareholders and other debtholders into profits. 13.90%

Insider trades

1,803,322.0 shares bought (9 transactions)

14,193.0 shares sold (2 transactions)

No purchases

No sells

No purchases

No sells

No purchases

No sells

Q1 2022 Q2 2022 Q3 2022 Q4 2022

About Incyte Corp.

CEO: Paul Friedman

Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)

Similar stocks

AMGEN Inc.
AMGEN Inc.
Ligand Pharmaceuticals, Inc. - Class B
Ligand Pharmaceuticals, Inc. - Class B
Lilly(Eli) & Co
Lilly(Eli) & Co
Pfizer Inc.
Pfizer Inc.
Geron Corp.
Geron Corp.
Ardelyx Inc
Ardelyx Inc
Novartis AG - ADR
Novartis AG - ADR
AVEO Pharmaceuticals Inc
AVEO Pharmaceuticals Inc
CTI BioPharma Corp
CTI BioPharma Corp

News

Eli Lilly and Company – Consensus Indicates Potential 5.5% Upside

Eli Lilly and Company – Consensus Indicates Potential 5.5% Upside

Eli Lilly and Company with ticker code (LLY) have now 23 analysts covering the stock with the consensus suggesting a rating of ''Buy''. The target price rang...

DirectorsTalk DirectorsTalk, 8 days ago
BriaCell Reports Positive Breast Cancer Efficacy Data with Bria-IMT™ Immunotherapy Treatment at SITC Annual Meeting

BriaCell Reports Positive Breast Cancer Efficacy Data with Bria-IMT™ Immunotherapy Treatment at SITC Annual Meeting

PHILADELPHIA and VANCOUVER, British Columbia, Nov. 10, 2022 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or t...

GlobeNewswire GlobeNewswire, 22 days ago
Incyte, Mirati team up for trial of combo therapy for solid tumors

Incyte, Mirati team up for trial of combo therapy for solid tumors

Incyte (INCY) and Mirati Therapeutics (MRTX) entered a clinical trial collaboration and supply agreement.The companies will evaluate a combination of Incyte'...

Seeking Alpha Seeking Alpha, 25 days ago
Incyte A Buy As Revenue From Opzelura Ramps (NASDAQ:INCY)

Incyte A Buy As Revenue From Opzelura Ramps (NASDAQ:INCY)

Incyte reported 20% y/y product revenue growth in Q3 2022 and Opzelura revenue grew $38 million y/y. Click here to read my latest analysis of INCY stock.

Seeking Alpha Seeking Alpha, 30 days ago
Never miss a trade
To improve your user experience we use cookies.